Clinical trial · Interventional
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
Humanized Anti-Tac Antibody Therapy In Hodgkin's Disease, A Phase Ib/II Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia or lymphoma cells. Combining these two therapies may be an effective treatment for leukemia and lymphoma. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy plus interleukin-2 in treating patients who have leukemia or lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aldesleukin | Biological | Aldesleukin | ALIAS |
| daclizumab | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of one of the following malignancies: * Hodgkin's lymphoma * Acute myelogenous leukemia * Chronic myelogenous leukemia * Failed standard therapy or in chronic phase if on standard therapy * At least 30% of malignant cells reactive with anti-Tac as determined by immunofluorescence studies * All Hodgkin's lymphoma patients eligible due to 100% Tac-positivity of Reed-Sternberg cells * Measurable disease * No symptomatic CNS disease PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * 0-2 Life expectancy: * Greater than 2 months Hematopoietic: * Not specified Hepatic: * Bilirubin no greater than 3 times normal * No significant hepatic disease Renal: * Creatinine no greater than 3 times normal * No significant renal disease Cardiovascular: * No significant cardiovascular disease Pulmonary: * No significant pulmonary disease Other: * No significant endocrine, rheumatologic, or allergic disease * No HIV-I antibody * No active disease due to any of the following: * Cytomegalovirus Herpes simplex virus I/II * Hepatitis B or C Tuberculosis * Negative pregnancy test required of fertile women PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior murine anti-Tac monoclonal antibody Chemotherapy: * At least 4 weeks since chemotherapy Endocrine therapy: * Not specified Radiotherapy: * At least 4 weeks since radiotherapy Surgery: * Not specified Other: * Concurrent treatment allowed for complications of primary disease
References
Publications (0)
Data not yet available